IQVIA Collaborating with Janssen Research & Development on Their Investigational COVID-19 Vaccine Trials
March 08 2021 - 8:00AM
Business Wire
IQVIA™ (NYSE: IQV) announces that since September 2020 it has
been collaborating with Janssen Research & Development, LLC,
one of the Janssen Pharmaceutical Companies of Johnson &
Johnson, on the Phase 3 COVID-19 vaccine clinical trials.
The studies leverage IQVIA’s suite of decentralized trial
solutions that support both on-site and remote study delivery
through a mix of telehealth technologies, virtual oversight, and
digital patient engagement strategies. These capabilities enabled
participants to be screened remotely to determine their risk
status, to schedule an appointment at a nearby site, and to report
potential COVID-19 symptoms and other study data remotely
throughout the study.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions, and clinical research services to
the life sciences industry. IQVIA creates intelligent connections
across all aspects of healthcare through its analytics,
transformative technology, big data resources and extensive domain
expertise. IQVIA Connected Intelligence™ delivers powerful insights
with speed and agility — enabling customers to accelerate the
clinical development and commercialization of innovative medical
treatments that improve healthcare outcomes for patients. With
approximately 70,000 employees, IQVIA conducts operations in more
than 100 countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing information on a scale that helps
healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better
outcomes. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap
into a deeper understanding of diseases, human behaviors and
scientific advances, in an effort to advance their path toward
cures. To learn more, visit www.iqvia.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210308005061/en/
Tor Constantino, IQVIA Media Relations
(tor.constantino@iqvia.com) +1.484.567.6732 Andrew Markwick, IQVIA
Investor Relations (andrew.markwick@iqvia.com) +1.973.257.7144
IQVIA (NYSE:IQV)
Historical Stock Chart
From Aug 2024 to Sep 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Sep 2023 to Sep 2024